Albany Molecular Res (AMRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2012 | 03-2012 | 12-2011 | 09-2011 | 06-2011 | |
| Sales | 50,009 | 53,695 | 46,592 | 50,229 | 53,877 |
| Cost of Goods | 37,004 | 40,769 | 41,072 | 46,034 | 41,977 |
| Gross Profit | 13,005 | 12,926 | 5,520 | 4,195 | 11,900 |
| Operating Expenses | 11,515 | 15,643 | 32,920 | 12,146 | 12,673 |
| Operating Income | 1,494 | -1,948 | -27,328 | -7,917 | 204 |
| Interest Expense | 113 | 142 | 387 | 205 | 83 |
| Other Income | 136 | -792 | 75 | 547 | -453 |
| Pre-tax Income | 1,517 | -2,882 | -27,640 | -7,575 | -332 |
| Income Tax | 1,260 | 925 | -3,231 | -1,723 | 236 |
| Net Income Continuous | 257 | -3,807 | -24,409 | -5,852 | -568 |
| Net Income | $257 | $-3,807 | $-24,409 | $-5,852 | $-568 |
| EPS Basic Total Ops | 0.01 | -0.13 | -0.82 | -0.19 | -0.02 |
| EPS Basic Continuous Ops | 0.01 | -0.13 | -0.81 | -0.19 | -0.02 |
| EPS Diluted Total Ops | 0.01 | -0.13 | -0.82 | -0.19 | -0.02 |
| EPS Diluted Continuous Ops | 0.01 | -0.13 | -0.81 | -0.19 | -0.02 |
| EBITDA(a) | $5,859 | $2,587 | $-6,990 | $-3,300 | $4,634 |